Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Aqua Bio Technology ASA's Debt-to-Equity or its related term are showing as below:
FRA:3FZ0'
s Debt-to-Equity Range Over the Past 10 Years
Min: -222.44 Med: 0.5 Max: 17.55
Current: 1.76
During the past 13 years, the highest Debt-to-Equity Ratio of Aqua Bio Technology ASA was 17.55. The lowest was -222.44. And the median was 0.50.
FRA:3FZ0's Debt-to-Equity is ranked worse than 93.46% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:3FZ0: 1.76
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Aqua Bio Technology ASA Debt-to-Equity Related Terms
Aqua Bio Technology ASA Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3FZ0 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Aqua Bio Technology ASA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aqua Bio Technology ASA Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aqua Bio Technology ASA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Aqua Bio Technology ASA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aqua Bio Technology ASA (FRA:3FZ0) has a Debt-to-Equity of 1.76 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aqua Bio Technology ASA and its competitors. This is 252% above median its historical median of 0.50. According to the industry distribution chart, Aqua Bio Technology ASA ranks #900 out of 963 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Aqua Bio Technology ASA's Debt-to-Equity too high?
Aqua Bio Technology ASA's current Debt-to-Equity of 1.76 is 252% above median its 10-year median of 0.50. The Biotechnology industry median Debt-to-Equity is 0.16. Aqua Bio Technology ASA's value of 1.76 is 1000% above this industry median. Based on the distribution chart, Aqua Bio Technology ASA ranks #900 out of 963 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aqua Bio Technology ASA has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Aqua Bio Technology ASA's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aqua Bio Technology ASA ranks #900 out of 963 companies for Debt-to-Equity. This places Aqua Bio Technology ASA in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Aqua Bio Technology ASA's value of 1.76 is 1000% above this benchmark. While the company's 10-year median is 0.50 vs. the industry median of 0.16, Aqua Bio Technology ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aqua Bio Technology ASA's current Debt-to-Equity of 1.76 is 1000% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aqua Bio Technology ASA and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aqua Bio Technology ASA's current Debt-to-Equity is 1.76, which is 252% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aqua Bio Technology ASA stock overvalued right now?
Aqua Bio Technology ASA (FRA:3FZ0) has a current Debt-to-Equity of 1.76. The stock's GF Value™ is €0.28, compared to a current price of €0.45 — trading 61.1% above its estimated fair value. The current Debt-to-Equity is 1.76, which is 252% above median its 10-year median of 0.50 and 1000% above the Biotechnology industry median of 0.16. Aqua Bio Technology ASA's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Aqua Bio Technology ASA (FRA:3FZ0), the current Debt-to-Equity is 1.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aqua Bio Technology ASA (FRA:3FZ0) Overvalued in 2026?
Based on GuruFocus' analysis, Aqua Bio Technology ASA stock appears to be overvalued.
The current stock price of €0.45 is trading 61.1% above its estimated GF Value™ of €0.28.
Key valuation signals for FRA:3FZ0:
Debt-to-Equity: 1.76 (252% above median its 10-year median of 0.50)
GF Value™: €0.28 vs. price of €0.45 (61.1% above fair value)
Industry Position: 1000% above the Biotechnology median (#900 of 963)
No single metric tells the full story. See the FRA:3FZ0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aqua Bio Technology ASA develops, produces and markets active ingredients for the personal care industry. It creates products for personal care, healthcare, and cosmetics with the help of marine biotechnology. ABT's brands include Moana-Organic skin care and Cuvget-Arctic skin care.
43GF Score
Get the complete analysis for FRA:3FZ0
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3FZ0 has been successfully added to your 
